1 of 1
Story summary
- Mass General Brigham researchers reported in JAMA that a blood test measuring p-tau217 can predict Alzheimer’s risk up to ten years before symptoms.
- Very high p-tau217 levels corresponded to a 38% five-year and a 78% ten-year risk of cognitive impairment.
- Researchers warned the test is not advised for asymptomatic people because no disease-modifying therapies exist, though experts note it could help recruit high-risk volunteers for future drug trials.
